✦ LIBER ✦

First-Line Gefitinib in Patients With Advanced Non-Small-Cell Lung Cancer Harboring Somatic EGFR Mutations

✍ Scribed by Sequist, L. V.; Martins, R. G.; Spigel, D.; Grunberg, S. M.; Spira, A.; Janne, P. A.; Joshi, V. A.; McCollum, D.; Evans, T. L.; Muzikansky, A.; Kuhlmann, G. L.; Han, M.; Goldberg, J. S.; Settleman, J.; Iafrate, A. J.; Engelman, J. A.; Haber, D. A.; Johnson, B. E.; Lynch, T. J.

Book ID: 118009083
Publisher: American Society of Clinical Oncology
Year: 2008
Tongue: English
Weight: 228 KB
Volume: 26
Category: Article
ISSN: 0732-183X
DOI: 10.1200/jco.2007.14.8494

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Influence of first-line chemotherapy and

Influence of first-line chemotherapy and EGFR mutations on second-line gefitinib in advanced non-small cell lung cancer

✍ Wu, Jenn-Yu; Yu, Chong-Jen; Shih, Jin-Yuan; Yang, Chih-Hsin; Yang, Pan-Chyr 📂 Article 📅 2010 🏛 Elsevier Science 🌐 English ⚖ 374 KB

First-Line Single Agent Treatment With G

First-Line Single Agent Treatment With Gefitinib in Advanced Non–Small-Cell Lung Cancer Patients

✍ Yong-mei Yin 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 37 KB

Miliary brain metastases in 2 cases with

Miliary brain metastases in 2 cases with advanced non-small cell lung cancer harboring EGFR mutation during gefitinib treatment

✍ Mochizuki, Sayaka; Nishimura, Naoki; Inoue, Akira; Murakami, Koji; Nukiwa, Toshi 📂 Article 📅 2012 🏛 Elsevier 🌐 English ⚖ 892 KB

Gefitinib as first-line, compassionate u

Gefitinib as first-line, compassionate use therapy in patients with advanced non-small-cell lung cancer

✍ Argiris, Athanassios; Mittal, Namrata 📂 Article 📅 2004 🏛 Elsevier Science 🌐 English ⚖ 90 KB

Gefitinib or Chemotherapy for Non–Small-

Gefitinib or Chemotherapy for Non–Small-Cell Lung Cancer with Mutated EGFR

✍ Maemondo, Makoto; Inoue, Akira; Kobayashi, Kunihiko; Sugawara, Shunichi; Oizumi, 📂 Article 📅 2010 🏛 Massachusetts Medical Society 🌐 English ⚖ 341 KB

Gefitinib or Chemotherapy for Non–Small-

Gefitinib or Chemotherapy for Non–Small-Cell Lung Cancer with Mutated EGFR

✍ Maemondo, Makoto; Inoue, Akira; Kobayashi, Kunihiko; Sugawara, Shunichi; Oizumi, 📂 Article 📅 2010 🏛 Massachusetts Medical Society 🌐 English ⚖ 341 KB

## Background: Non-small-cell lung cancer with sensitive mutations of the epidermal growth factor receptor (egfr) is highly responsive to egfr tyrosine kinase inhibitors such as gefitinib, but little is known about how its efficacy and safety profile compares with that of standard chemotherapy. ##